ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ARGX argenx SE

494.46
8.13 (1.67%)
取引時間後
最終更新日: 06:30:00
15分遅延
名称 銘柄コード 市場 種別
argenx SE ARGX NASDAQ Depository Receipt
  前日比 前日比 % 現在値 時刻
8.13 1.67% 494.46 06:30:00
始値 安値 高値 終値 前日終値
476.04 473.67 495.50 494.46 486.33
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/7/2519:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/7/2514:00GLOBEargenx Reports Half Year 2024 Financial Results and Provides..
2024/7/1814:00GLOBEargenx to Report Half Year 2024 Financial Results and Second..
2024/7/1706:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/7/1705:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/7/1613:30GLOBEargenx and Zai Lab Announce Approval of Efgartigimod Alfa..
2024/7/1613:15BWZai Lab and argenx Announce Approval of Efgartigimod Alfa..
2024/6/2605:30GLOBEargenx Highlights Breadth of Autoimmune Pipeline with New..
2024/6/2205:50GLOBEargenx Announces FDA Approval of VYVGART Hytrulo for Chronic..
2024/6/1719:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/6/1714:00GLOBEargenx to unveil its ‘Vision 2030: Taking Breakthrough..
2024/6/0414:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
2024/5/0920:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/5/0914:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
2024/5/0819:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/5/0806:30GLOBEargenx announces results of Annual General Meeting of..
2024/5/0714:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
2024/5/0214:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
2024/4/1614:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
2024/3/2715:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
2024/3/2705:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
2024/3/2615:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
2024/3/0820:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/3/0806:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
2024/3/0106:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2915:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
2024/2/2615:00GLOBEargenx to Present at Upcoming Investor Conferences
2024/2/2215:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
2024/2/2020:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2015:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
2024/1/1820:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/1815:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
2024/1/0820:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0815:00GLOBEargenx Highlights 2024 Strategic Priorities
2024/1/0215:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
2023/12/2102:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
2023/12/2020:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2015:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
2023/11/2901:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
2023/11/2821:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
2023/11/2820:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/2815:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
2023/11/1720:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/1621:40GLOBEargenx Announces European Commission Approval of..
2023/11/0205:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0115:00GLOBEargenx to Present at Upcoming Investor Conferences
2023/10/3122:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/3115:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
2023/10/2414:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
2023/9/2805:42EDGAR2Form S-8 - Securities to be offered to employees in employee..

最近閲覧した銘柄

Delayed Upgrade Clock